Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.64 | N/A | +6.29% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.64 | N/A | +6.29% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding current market conditions. They focused on future product pipelines as a key area of growth.
Management highlighted ongoing challenges in the market.
They emphasized the importance of upcoming product developments.
The earnings report shows that while Alnylam Pharmaceuticals beat expectations on EPS, the lack of revenue data and guidance has raised concerns among investors. The stock reacted negatively, dropping 2.68%. This suggests uncertainty about the company's future performance and market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Apr 26, 2021